PTC Therapeutics, Inc. Proceeds from Issuance of Secured Debt
PTC Therapeutics, Inc. (PTCT) reported Proceeds from Issuance of Secured Debt of $300.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSecuredDebt · last filed 2025-02-27
- PTC Therapeutics, Inc. proceeds from issuance of secured debt for fiscal 2022 was $300.00M.
- PTC Therapeutics, Inc. proceeds from issuance of secured debt for fiscal 2019 was $0.00.
- PTC Therapeutics, Inc. proceeds from issuance of secured debt for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- PTC Therapeutics, Inc. proceeds from issuance of secured debt for fiscal 2017 was $40.00M.
| Period end | Proceeds from Issuance of Secured Debt 12 month |
|---|---|
| 2022-12-31 | $300.00M 10-K · filed 2025-02-27 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-02 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-02 |
| 2017-12-31 | $40.00M 10-K · filed 2020-03-02 |
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |